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Background: An understanding of the mechanisms mediating protective immunity against malaria in humans is
currently lacking, but critically important to advance the development of highly efficacious vaccines. Antibodies
play a key role in acquired immunity, but the functional basis for their protective effect remains unclear.
Furthermore, there is a strong need for immune correlates of protection against malaria to guide vaccine
development.
Methods: Using a validated assay to measure opsonic phagocytosis of Plasmodium falciparum merozoites, we
investigated the potential role of this functional activity in human immunity against clinical episodes of malaria in
two independent cohorts (n = 109 and n = 287) experiencing differing levels of malaria transmission and evaluated
its potential as a correlate of protection.
Results: Antibodies promoting opsonic phagocytosis of merozoites were cytophilic immunoglobulins (IgG1 and IgG3),
induced monocyte activation and production of pro-inflammatory cytokines, and were directed against major
merozoite surface proteins (MSPs). Consistent with protective immunity in humans, opsonizing antibodies were
acquired with increasing age and malaria exposure, were boosted on re-infection, and levels were related to
malaria transmission intensity. Opsonic phagocytosis was strongly associated with a reduced risk of clinical malaria
in longitudinal studies in children with current or recent infections. In contrast, antibodies to the merozoite surface
in standard immunoassays, or growth-inhibitory antibodies, were not significantly associated with protection. In
multivariate analyses including several antibody responses, opsonic phagocytosis remained significantly associated
with protection against malaria, highlighting its potential as a correlate of immunity. Furthermore, we demonstrate
that human antibodies against MSP2 and MSP3 that are strongly associated with protection in this population are
effective in opsonic phagocytosis of merozoites, providing a functional link between these antigen-specific
responses and protection for the first time.
Conclusions: Opsonic phagocytosis of merozoites appears to be an important mechanism contributing to
protective immunity in humans. The opsonic phagocytosis assay appears to be a strong correlate of protection
against malaria, a valuable biomarker of immunity, and provides a much-needed new tool for assessing responses
to blood-stage malaria vaccines and measuring immunity in populations.
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Knowledge of the mechanisms that mediate protective
immunity against Plasmodium falciparum malaria in
humans is currently very limited, and this has been a major
barrier to vaccine development. In malaria-endemic areas
the severity and frequency of clinical malaria declines with
increasing age and repeated exposure to infections, reflect-
ing the acquisition of specific immunity [1]. Antibodies are
known to be key components of naturally-acquired im-
munity against P. falciparum [1,2], and passive transfer of
immunoglobulins from immune donors to individuals with
P. falciparum infection has been shown to reduce parasit-
emia and clinical symptoms [3,4]. Merozoites are a major
target of these acquired antibody responses [5-8]. However,
the mechanisms mediating protective humoral immunity
and the key targets of functional antibodies remain poorly
understood. In addition, there is a lack of strong immune
correlates of protective immunity for use in vaccine
development and population monitoring in malaria
control programs [9]. The growth inhibition assay
(GIA) is the only widely used functional assay in studies
of acquired human immunity and candidate blood-stage
vaccines [10]. However, associations between growth-
inhibitory antibodies and protective immunity have been
weak and inconsistent [10-13], implying that other mecha-
nisms are important, but these remain undefined. Recently,
a neutrophil-based antibody-dependent respiratory burst
(ADRB) assay was shown to be a correlate of acquired
immunity in two endemic populations in Senegal, but
these findings have not as yet been reproduced in other
cohort studies in Africa [14].
We investigated the role of antibody-mediated opsonic
phagocytosis of P. falciparum merozoites by monocytes.
Human antibodies to P. falciparum merozoites are pre-
dominantly of the cytophilic (IgG1 and IgG3) sub-types
that interact with monocytes and other cells, via Fc-gamma
receptors [8,15-17]. In addition to direct clearance of
merozoites, opsonic phagocytosis by monocytes may
also stimulate the release of cytokines or other media-
tors that subsequently promote parasite killing [18].
Although prior studies have shown that antibodies can
promote phagocytosis of merozoites [19-21], how these
antibodies are acquired and/or boosted is unknown,
and their targets and relationships to other immune
measures have not been defined. There are no longitudinal
studies of these responses in African children who are
at the greatest risk of malaria or studies to define how
they are acquired and/or boosted.
We developed and validated an efficient assay with
good throughput to measure antibody-mediated opsonic
phagocytosis of merozoites using the human monocytic
THP-1 cell line. We studied the properties of opsonic
phagocytosis antibodies, identified merozoite target anti-
gens and demonstrated resultant monocyte activation. Indetailed longitudinal studies of African children we defined
the acquisition of opsonic phagocytosis antibodies, and
show they are strongly associated with protection
against malaria, suggesting opsonic phagocytosis anti-
bodies could be used as a valuable correlate of protection
in malaria vaccine development.
Methods
Study population
Two different longitudinal cohort studies, referred to as
Chonyi and Ngerenya, were included to address different
aspects of the acquisition and boosting of antibodies,
their relationship to immunity, and the impact of mal-
aria transmission rates on antibodies. Details of the
study area and population are published [22]. Malaria
transmission occurs in two seasonal peaks, with average
annual entomological inoculation rates (EIRs) of 20 to
53 (Chonyi), and 10 (Ngerenya) infective bites/person/
year [23,24]. Briefly, participants were recruited during
cross-sectional surveys in October 2000 (Chonyi, n = 536)
and October 2002 (Ngerenya, (n = 295)), at the start of
a malaria transmission season. A single blood sample
was collected at recruitment and participants were
subsequently monitored actively each week for six
months to detect clinical episodes of malaria. Regular
screening for parasitemia was not performed during
the follow up visits, but was measured only when par-
ticipants reported any symptoms suggestive of malaria.
Local age-specific criteria defining clinical episodes of
malaria were: fever (>37.5°C) plus any parasitemia for
children less than one year old, and fever plus a para-
sitemia >2,500/μL for participants older than one year
[22]. In Ngerenya, children also underwent active sur-
veillance for malaria in the six months prior to sample
collection. In this report, data are presented for all
children from Ngerenya for whom a sample was available
(n = 287) and the subset of children from Chonyi who
were asymptomatically parasitized (parasite-positive) at
the time of sampling (n = 109). For Chonyi, this subset
was studied for two main reasons; firstly, although the ori-
ginal cohort was made up of children and adults, 90% of
all clinical episodes observed during six months of moni-
toring occurred in children ≤10 years old; therefore, adults
were excluded from the analysis of antibodies in relation
to the risk of clinical malaria. Secondly, protective associa-
tions have only been observed in the subset of children
who were asymptomatically parasitized (parasite-positive)
at recruitment and the incidence of malaria in those
who were parasite negative at enrollment was low
[6,25-30]. Therefore, this subset was considered ideal
to test the hypothesis that the phagocytosis index was
a correlate of protective immunity against clinical episodes
of malaria, and comprised children up to ten years of age
who were parasite positive at recruitment (n =109). For
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and validation of the assay, and for performing detailed
comparisons between opsonic phagocytosis and other
measures of malaria immunity, a random selection of
samples from Ngerenya children and adults (n = 33)
was used for which we had sufficient volumes of sera to
perform multiple antibody testing. Total immunoglobulin
G (IgG) was also purified from these samples for use in as-
says. Pooled serum from 20 adult blood donors from the
same village was used to affinity-purify antigen-specific
antibodies. A reference Malaria Immune Globulin (MIG)
reagent (Central Laboratory of the Swiss Red Cross Blood
Transfusion Service, Berne Switzerland) [31] was used for
validation experiments and as a positive control for the
cohort assays. This preparation contains 50 mg/ml of
immunoglobulins (98% IgG) purified from a pool of
healthy Malawian adult plasma and was originally man-
ufactured to test its potential use as an adjunct therapy
to quinine in the treatment of cerebral malaria. Written
informed consent was obtained from all study partici-
pants or their parents/guardians. Ethical approval was
granted by the Kenya National Research Ethics Review
Committee (SSC No. 1131).
Laboratory methods
Culture of THP1 cells
THP1 cells were maintained in Roswell Park Memorial
Institute (RPMI)-1640 with 0.002 mol/L L-glutamine,
1.5 g/L sodium bicarbonate, 0.01 mol/L HEPES, 5 × 10−5
mol/L 2-mercaptoethanol, and 10% fetal bovine serum
[32]. Cell density was monitored closely and main-
tained between 1 × 105 and 1 × 106 cells/mL. Cells were
passaged every six days, when cell density approached
1 × 106 cells/mL.
Culture of Plasmodium falciparum
The laboratory-adapted P. falciparum line D10 was cul-
tured in RPMI- N-2-hydroxyethylpiperazine-N-2-ethane
sulfonic acid (HEPES) with 0.5% Albumax and 0.18%
NaHCO3 [33]. Cultures were maintained below 10% para-
sitemia and synchronized by sorbitol treatment.
Isolation of free merozoites
Merozoites were isolated directly from culture using
previously published methods [34,35]. Briefly, late stage
pigmented trophozoites were harvested by magnetic
purification on columns and then cultured in medium sup-
plemented with the protease inhibitor trans-epoxysuccinyl-
L-leucylamido(4-guanidino) butane (E64) for eight hours to
allow maturation to schizonts without rupture. Mature
schizonts were collected and passed through a 1.2 μm
filter to release and purify merozoites. Free merozoites
were stained with ethidium bromide (EtBr) at a final
concentration of 1 μg/mL for 30 minutes followed by threewashes in RPMI. The cell density was determined using
relative counting against CountBright™ Absolute Counting
Beads (Invitrogen, Mount Waverly, Victoria, Australia) on a
BD FACSCalibur (BD Biosciences, North Ryde, New South
Wales, Australia) flow cytometer. The merozoites were then
resuspended at 5 × 107 merozoites/mL in RPMI-HEPES
and used in assays as described.
Isolation of human peripheral blood mononuclear cells
Human peripheral blood was collected into ethylenedi-
aminetetraacetic acid (EDTA)-coated vacutainers from
malaria naïve donors. Whole blood was diluted with an
equal volume of PBS and overlayed on 15 ml of Ficoll.
The tube was centrifuged at 400 × g for 40 minutes before
collection of the buffy coat. Cells were washed three times
with PBS supplemented with newborn calf serum (NCS)
and resuspended in RPMI-1640 supplemented with
10% human serum. The peripheral blood mononuclear
cells (PBMCs) were then stored at 4°C until use.
Phagocytosis using undifferentiated THP-1 cells
Our method was adapted from an established assay for the
opsonic phagocytosis of P. falciparum-infected erythrocytes
by undifferentiated THP-1 cells [36,37]. Briefly, freshly cul-
tured THP-1 cells were counted and resuspended at a final
concentration of 5 × 105/mL in THP-1 culture medium.
Freshly isolated merozoites were transferred into 96-well
U-bottomed plates (30 μL/well at 5 × 107 merozoites) that
had been pre-coated with fetal calf serum (FCS) (200 μL of
FCS, incubated for one hour, followed by a single wash with
incomplete RPMI). All antibodies used for opsonization
were heat inactivated to exclude any influence of comple-
ment. For opsonization, 3.5 μL of test serum was incubated
with 30 μL of merozoites (pre-stained with EtBr) for
one hour at room temperature in the dark. The plate
was washed three times using incomplete RPMI, before
resuspension in 150 μL THP-1 culture medium. To obtain
three replicates, 50 μL of the opsonized merozoites were
co-incubated with 100 uL each of THP-1 cells at 5 × 105
cells/mL in FCS at 37°C for 10 minutes for phagocytosis.
Phagocytosis was stopped by the addition of 50 μL cold
PBS supplemented with NCS. Plates were immediately
washed to remove free or loosely attached merozoites.
Three washes were performed using the same buffer at 4°C
(centrifugation at 300 × g for four minutes). THP-1 cells
were then fixed with 2% paraformaldehyde (PFA) for two
hours before analysis by flow cytometry. Several controls
were included for each assay: 1) non-opsonized merozoites;
2) merozoites opsonized with non-malaria exposed sera;
and 3) merozoites opsonized with pooled highly reactive
sera from adults exposed to malaria (MIG). Selected assays
had an additional control in which THP-1 cells were pre-
incubated with cytochalasin D to inhibit phagocytosis. Flow
cytometry was performed in a 96-well format on a BD
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ments we established that a ratio of merozoites:THP-1 cells
of 10:1 was optimal. The level of phagocytosis was deter-
mined by counting the percentage of THP-1 cells that had
ingested merozoites and is referred to as the Phagocytosis
Index (PI). Results are presented as a relative phagocytosis
index (RPI%), with the PI being expressed as a ratio to that
of a standard positive control run in each assay. Samples
were considered positive for phagocytosis if the RPI
exceeded the mean plus three standard deviations of a
panel of 10 non-malaria exposed sera from Melbourne
blood donors (Melbourne controls).
Phagocytosis using freshly isolated peripheral blood
mononuclear cells
Isolated human PBMC were resuspended in RPMI-1640
supplemented with 10% FBS at a final concentration of
5 × 106/mL. Freshly isolated merozoites were opsonized
and stained with EtBr followed by co-incubation with
PBMCs for 10 minutes. The monocyte population was
gated on flow-cytometry dot plots using light scatter
characteristics and the percentage of EtBr positive mono-
cytes used to determine the phagocytosis index.
Immunofluorescence staining for monocyte
activation markers
Isolated PBMCs were resuspended in RPMI-1640 sup-
plemented with 10% human serum at a concentration of
5 × 106/mL. PBMCs (100 μL) were added to polypropyl-
ene tubes and kept on ice. Freshly isolated merozoites
were opsonized with either hyper-immune human IgG
or serum from malaria-naïve Melbourne donors for one
hour before being re-suspended in RPMI-1640 supple-
mented with 10% human serum at a concentration of
5 × 107/mL. Merozoites (10 μL) were added to the
PBMCs and co-incubated at 37°C for six hours. Brefeldin A
and Monensin were added to each tube at concentration of
1:1000 and 1:1500, respectively, prior to co-incubation.
Cells were then washed with cold fluorescence-activated
cell sorting (FACS) buffer after co-incubation and
monocytes were labelled by staining with anti-CD14-APC
antibodies. Cells were stained with anti-CD69-V450 to
determine monocyte activation [38-40]. The cells were
fixed overnight with BD FACS fix buffer (BD Biosciences)
then permeabilized with BD Perm/wash buffer. Production
of intracellular tumor necrosis factor- α (TNF-α) was
detected by staining with anti-TNF-α -PE antibodies.
Cells were re-suspended in BD Fix buffer following
intracellular staining.
Scanning electron microscopy
Square glass coverslips (22 mm) were prepared by smearing
with a 0.1% solution of polyethyleneimine (PEI) and
then dried. Cell samples were incubated on PEI-coatedglass coverslips for half an hour. Following incubation,
the excess sample was drained, and coverslips with ad-
hered cells were immersed in 2% glutaraldehyde in PBS
for one hour. Coverslips were then rinsed three times
in PBS for 10 minutes each before being dehydrated in
increasing concentrations of ethanol consisting of 10,
20, 40, 60, 80 and 100% ethanol in water for 10 minutes
for each step. The coverslips were then dried in a Balzers
CPD 030 Critical Point Dryer (Balzers Pfeiffer, Balzers,
Liechtenstein) and mounted onto 25-mm aluminum stubs
with double-sided carbon tabs and then gold-coated in a
Dynavac ‘Xenosput’ magnetron sputter coater (Dynavac,
Hingham MA, USA). The cells on coverslips were imaged
with the Philips XL30 field emission scanning electron
microscope (Philips, Eindhoven, Netherlands) at a volt-
age of 2 kV.
Fluorescence microscopy
Merozoites were stained with Hoechst after opsonization
with purified IgG from malaria-exposed Kenyan adult
sera after which they were co-incubated with THP-1
cells. The THP-1 cells were then resuspended in 2%
PFA and mounted on a glass slide. The slides were im-
mediately analyzed by Zeiss Cell Observer (North Ryde,
New South Wales, Australia. using a 100× magnification
object lens.
Affinity purification of human and rabbit antigen-specific
anti-merozoite antibodies
Human antibodies against the K1 allelic version of MSP3
[41] and the FC27 allele of MSP2 [42] of P. falciparum were
affinity purified from a 50 mL pool of plasma taken from
malaria semi-immune adults in Kenya (described under
Study Populations, n = 20) by column chromatography
(CNBr-activated SepharoseTM 4B, GE Healthcare),
according to the manufacturer's instructions, and as
previously described [43].
Whole merozoite ELISA
Purified whole merozoites [34,35] were resuspended in
PBS supplemented with a cocktail of protease inhibitors
(Roche, Castle Hill NSW, Australia). Whole merozoites
were then plated in NUNC Maxisorp™ plates at 100 μL
per well and incubated at 37°C for two hours (or overnight
at 4°C), followed by six washes with PBS. The plates were
then blocked with 200 μL of 1% casein in PBS at 37°C for
two hours followed by two washes with PBS. Serum sam-
ples were diluted at 1:1000 in PBS and 100 μL of each
sample was added to the ELISA plates in duplicate and
incubated at 37°C for one hour, followed by six washes in
PBS. The plates were further incubated with 100 μL per
well of horseradish peroxidase (HRP)-conjugated goat
anti-human IgG antibody diluted at 1:2500 in 0.1% PBS-
casein at 37°C for one hour followed by six washes with
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oxidase conjugated anti-human IgG1/IgG3 antibodies
were diluted at 1:1000 in 0.1% PBS-casein. Finally, 100 μL
of 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid)
(ABTS) was added to each well and incubated for 20
minutes for color development. The reaction was stopped
by the addition of 100 μL 1% SDS solution. Color develop-
ment was quantified at 405 nm. Pooled human IgG from
malaria exposed Kenyan adults was used at 1:1000 di-
lution as a positive control and individual sera from
malaria non-exposed Melbourne adults were used at
1:1000 dilution as negative controls.
Data analysis
Data were analyzed using Prism 5 (GraphPad Software,
Inc) and Stata 11 (StataCorp). For the Ngerenya cohort, the
presence/absence of phagocytosis was analyzed in relation
to single and multiple clinical episodes of malaria using the
modified Poisson regression model [44]. Subgroup analyses
were performed for children who had recent exposure
to malaria (positive malaria slide) in the six months be-
fore samples were collected. In Chonyi, >94% of chil-
dren were positive for phagocytosis, precluding the use
of the presence/absence of phagocytosis to relate to
malaria risk. However, the levels of phagocytosis were
nearly normally distributed allowing us to define three
levels of phagocytosis by tertiles: high, medium and low.
Risk of malaria episodes was analyzed for each tertile
using standard survival analysis techniques [17]. All
analyses included age as a potential confounder.
Results
Human antibodies promote phagocytosis of merozoites
We developed and validated an assay to measure op-
sonic phagocytosis using the human monocyte THP-1
cell line and purified intact merozoites isolated using
recently established methods [34,35]; we refer to these as
opsonic phagocytosis assays (OPA). We demonstrated that
antibody-mediated opsonic phagocytosis: (1) was spe-
cific to the IgG fraction of malaria-exposed sera in a
dose-dependent manner; (2) was inhibited by pre-treatment
of THP-1 cells with cytochalasin D, which is a known
inhibitor of macrophage and monocyte phagocytosis;
(3) was comparably quantified using either THP-1 cells or
freshly isolated human PBMCs; and (4) robustly measured
the internalization of merozoites into phago-lysosomes,
as demonstrated by staining merozoites with the pH-
dependent dye pHrodo™, which only becomes fluorescent
in the acid environment of phago-lysosomes (Figure 1A-D).
We found equivalent levels of phagocytosis using merozo-
ites stained with pHrodo™, compared to those stained
with EtBr, indicating that our assay robustly quantified in-
ternalized merozoites and was not confounded by surface
bound merozoites. Opsonic phagocytosis was optimallydetected at 10 minutes [see Additional file 1: Figure S1],
and our OPA gave results that were reproducible over a
wide range of phagocytic activity [see Additional file 1:
Figure S2]; we demonstrated activity using merozoites
purified from several different P. falciparum isolates
(isolates D10, 3D7, E8B, CS2, W2mef ). Opsonic phago-
cytosis led to activation of monocytes demonstrated by
increased intracellular TNF-α production, which is
thought to play an important role in parasite clearance
and immunity [18], and up-regulated CD69 expression
(Figure 2A-B). Scanning electron microscopy captured
striking images showing attachment of merozoites to
THP-1 cells and the commencement of phagocytosis
and internalization (Figure 3A). Internalized merozoites
could also be clearly seen using immunofluorescence
microscopy (Figure 3B).
Relationship to other measures of immunity
Antibody responses were studied in detail in a subset
of samples (n = 33) from children and adults to define
relationships between opsonic phagocytosis antibodies
and other measures of immunity. To understand better
the antibodies promoting phagocytosis and the rela-
tionship between antibody binding to the surface of
merozoites with OPA, we developed an assay to meas-
ure antibodies to intact merozoites by ELISA. Activity
in OPA was significantly and positively correlated with
IgG reactivity against intact purified merozoites, and
mediated predominantly by IgG1 and IgG3 subclasses
(Figure 4A-B). The GIA is currently the most widely
used functional assay for anti-merozoite antibodies, but
has not been consistently associated with protection in
naturally-acquired or vaccine-induced immunity. We found
that opsonic phagocytosis was only weakly correlated
with the ability of the same purified IgG to inhibit para-
site growth in a standard GIA (Spearman’s rho −0.358,
P = 0.041, Figure 4C); similarly, total IgG against whole
merozoites was also only weakly correlated with inhibi-
tory activity in GIAs (Spearman’s rho −0.410, P = 0.018,
Figure 4D). Others have reported variable correlations
(negative, positive and non-significant) between growth
inhibitory antibodies and exposure, or antibodies to mero-
zoite surface proteins (MSPs), in some African populations
[11,12,45], including Kenya, which has raised questions
about the GIA as a correlate of human immunity.
Acquisition of human antibodies promoting
opsonic phagocytosis
We next measured opsonic phagocytosis activity in samples
from two separate longitudinal cohort studies of children
performed in two sites with different levels of malaria trans-
mission. Transmission intensity was low in Ngerenya and
samples were available for 287 children, 0.1- to 8-years
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Figure 1 Phagocytosis assay validity. (A) Phagocytosis of whole merozoites is specific to malaria-immune sera and efficiently inhibited by
treatment with cytochalasin D. (B) The IgG fraction purified from serum mediates phagocytosis in a concentration dependent fashion, in assays
using cultured THP-1 cells and freshly isolated PBMCs. (C) Flow cytometry histogram overlay contrasting the phagocytosis in monocytes from
human PBMCs when freshly isolated merozoites are opsonized with purified IgG from malaria-immune adults (grey line) with unopsonized
merozoites (black line). (D) Equivalent levels of phagocytosis obtained when merozoites were stained with the pH dependent dye pHrodoTM or
with ethidium bromide, indicating internalization of merozoites into acidic phago-lysosomes. Experiments were conducted using malaria-immune
IgG (MIG). PBMCs. peripheral blood mononuclear cells.
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intensity was medium-to-high in Chonyi (109 children,
1- to 10-years old, who were all asymptomatically infected
at the time of blood sampling).
In Ngerenya, 48% had antibodies mediating phagocytosis.
This proportion rose to 90% among those who had asymp-
tomatic infections at the time of sampling (Figure 5A),
suggesting that active infection boosted opsonic anti-
bodies. In Chonyi, where all children had asymptomatic
infections, the prevalence of phagocytosis mediating
antibodies was comparably high at 94.5% (Figure 5A). In
both cohorts, the OPA activity positively correlated
with age, reflecting increasing cumulative exposure to
P. falciparum; this was statistically significant in the
Ngerenya cohort (Figure 5B), but not in Chonyi (Figure 5C).
In Ngerenya, the RPI was significantly higher in children
who had active P. falciparum infections at sampling
compared to aparasitemic children (Figure 5D). Opsonicphagocytosis was also higher for children who had
P. falciparum infections in the six months prior to
sample collection compared to those who had not been
infected (mean RPI 33.4 versus 14.1, P <0.001), again
indicating efficient boosting of opsonic phagocytosis.
In contrast, growth-inhibitory antibodies were no different
among children with infection in the preceding six
months than in those without (mean growth inhibition
98.9% versus 98.7%, P = 0.867, Figure 5E), or those with
concurrent parasitemia versus uninfected. The RPI was
also significantly higher in age-matched children from
Chonyi than in those from Ngerenya, consistent with the
differences in malaria transmission intensity (Figure 5F).
In Ngerenya, children less than six months of age had a
higher RPI compared to those within the six-months to
one-year age-group, suggesting placentally-transferred
maternal opsonic phagocytosis antibodies (mean RPI 18.11
versus 5.22, P = 0.013).





























Figure 2 Monocyte activation and cytokine production following
phagocytosis of merozoites. Production of intracellular TNF-α (A)
and surface expression of CD69 (B) was significantly elevated in the
monocytes co-incubated with malaria-immune IgG (MIG) opsonized
merozoites (black solid line), while that in monocytes co-incubated
with merozoites opsonized with non-immune Melbourne sera
(grey solid line) was no different from baseline levels detected
before phagocytosis (dark dotted line).
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of merozoites
Chonyi cohort
No longitudinal studies of antibody opsonic phagocytosis
of merozoites by monocytes/macrophages to examine
the relationship with protective immunity have been re-
ported in African populations where most P. falciparum
malaria occurs. Here, we found that children with the
highest levels of phagocytosis had a significant andstrongly reduced risk of symptomatic malaria compared
to those with low level responses (age-adjusted hazard
ratio (HR) 0.25 (0.10 to 0.60), P = 0.002; Figure 6A; Table 1).
In contrast, neither total IgG nor cytophilic IgG1/IgG3
antibodies against whole merozoites measured by ELISA
were significantly associated with protection from malaria
(Figure 6B-C, Table 1). This indicated that although the
whole merozoite ELISA was simpler to perform, the OPA
measuring functional antibodies was a better measure of
protective immunity to malaria.
A previous study in this population found that the
breadth of antibody responses to merozoite antigens
was strongly associated with protection [6]. Breadth
was defined as the sum of IgG responses against a panel
of recombinant merozoite antigens, apical membrane
antigen 1 (AMA1), MSP-2, MSP-3, erythrocyte-binding
antigen 175 (EBA175), MSP-119 and MSP-1 block 2 [6].
Here, we found that opsonic phagocytosis activity in-
creased significantly with increasing breadth of specific
anti-merozoite antibody responses (Figure 6D-F). The
strength of association between opsonic phagocytosis and
protection against clinical episodes of malaria was similar
to that previously observed with antibodies against anti-
gens on the merozoite surface, MSP2, MSP3 and AMA1
[6] (Table 1). To assess this further, we fitted all antibody
measures in a single multivariate model. We chose to fit
all anti-merozoite antibody measures, and not only those
that were significantly associated with protection, because
each antigen on its own, or with others, was a likely candi-
date target of protective immunity or plausible biological
target, and represented a unique antigen (as opposed to
allelic versions of the same antigen). We found that only
opsonic phagocytosis activity and IgG to MSP2 remained
significantly and strongly associated with protective
immunity, suggesting an important role for opsonic
phagocytosis in human immunity to malaria (Table 2),
and identifying the OPA as a strong candidate for
much-needed correlates of protection. A similar multivari-
ate analysis only including responses associated with pro-
tection identified in the univariate analysis, did not change
this result [see Additional file 1: Table S1].
Antibody responses to schizont protein extract had
also been measured in this cohort in a previous study
[6] as a crude marker of malaria blood-stage exposure.
In the current study, we chose to assay responses to
intact merozoites, purified as described above for the
phagocytosis assays. We reasoned that IgG to intact
merozoites would be a better comparison with OPA
activity than responses against schizont protein ex-
tract that is contaminated with erythrocyte and para-
site debris, and contains many intracellular proteins
that are not targets of opsonic phagocytosis. We found
that ELISA responses against schizont extract and
those against whole merozoites were highly correlated
THP-1
-1




Figure 3 Visualization of opsonic phagocytosis of merozoites by THP-1 cells. (A) Scanning electron microscopy of THP-1 cells before and
during ingestion of merozoites. (B) Immunofluorescence microscopy of phagocytosis of merozoites opsonized with purified IgG from
malaria-immune adults (MIG). THP-1 cells were visualized by differential interference contrast (DIC), while merozoites were visualized with Hoechst
(blue). Figures represent data acquired from at least two independent experiments.
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IgG1 and IgG3 against whole merozoites, respectively).
IgG to schizont protein extract by ELISA was not signifi-
cantly associated with protection, HR 0.74(0.35 to 1.55),
P = 0.435. Fitting either IgG to schizont extract or to whole
merozoites did not change the results or interpretation of
the multivariate analysis [see Additional file 1: Table S1].
We also tested whether the OPA was correlated with
parasite density in peripheral blood samples among
subjects at the time of sampling, when these children
were asymptomatically infected. We found that OPA
was negatively correlated with parasite density (Cuzick
test for trend across ordered groups z = −1.70, P = 0.090).
Although this was of borderline or weak statistical signifi-
cance, it further suggests that the opsonic phagocytosis of
merozoites may contribute to controlling parasite densities.
Ngerenya cohort
The design of the Ngerenya cohort enabled us to investi-
gate the acquisition and boosting of antibodies following
infection relative to subsequent protective immunity in
young children in the early stages of acquiring immunity;
99/287 children experienced one episode of clinical malaria
during the six-month follow-up after sample collection
and antibody measurement, and 36 experienced ≥2
clinical episodes. Antibodies promoting phagocytosis
were associated with a significantly lower risk of multiple
episodes of malaria, only in the sub-group of childrenwho had recent previous exposure (Table 3), suggesting
antibodies were boosted by reinfection to levels that medi-
ate immunity. In contrast, total IgG reactivity to the mero-
zoite surface measured by ELISA was not associated with
a reduced risk of malaria (Table 3). These results were not
changed when both OPA antibodies and merozoite ELISA
antibodies were fitted to a single model for multivariate
analysis [see Additional file 1: Table S2].
Merozoite surface antigens as targets of opsonic
phagocytosis antibodies
Prior studies showed that antibodies to MSP2 and MSP3
measured by ELISA were the antigen-specific responses
most strongly associated with protective immunity in
our study population [6]; IgG to MSP2 remained signifi-
cantly associated with protection in our multivariate
analysis described above. We sought to understand the
function of these target-specific antibodies, given that
they have limited activity in standard GIAs [46-48].
We affinity-purified human antibodies using recom-
binant MSP2 and MSP3 from a pool of sera from Kenyan
adult residents with extensive malaria exposure. These
antigen-specific affinity-purified antibodies showed
strong concentration-dependent opsonic phagocytosis
activity compared to the unopsonized control (Figure 7),
providing the first evidence of a mechanism that may
account for this protective association, and identifying
























































































Figure 4 Characteristics of antibodies promoting phagocytosis. (A) Pairwise correlation between the relative phagocytosis index and IgG
ELISA optical density (OD) against whole merozoites. (B) IgG subclasses against whole merozoites measured by ELISA. (C) Pairwise correlation
between the relative phagocytosis index and parasite growth inhibition measured in the GIA. (D) Pairwise correlation between IgG ELISA OD
against whole merozoites and GIA. Data from GIAs (C and D) are expressed as parasite growth (%), relative to malaria-naive controls. Experiments
were conducted using purified IgG from adults and children in Ngerenya , n = 33. GIA, growth inhibition assay.
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Passive transfer experiments conducted nearly 50 years
ago provided clear evidence of the importance of anti-
bodies in protection against malaria [3]. However, the
mechanisms and targets underlying antibody-mediated
immunity remain unclear and have proved challenging
to define, yet are essential for advancing vaccine develop-
ment and developing tools to monitor malaria exposure
and immunity in populations [49]. Furthermore, a lack of
reliable immune correlates of protection has hindered
malaria blood-stage vaccine development. Here, we pro-
vide major new evidence that antibody-dependent opsonic
phagocytosis of merozoites is an important mechanism
in acquired human immunity, contributing to the con-
trol of parasitemia in vivo. We demonstrate that opsonic
phagocytosis of merozoites is mediated by IgG, primarily
through cytophilic IgG1 and IgG3 antibodies to merozoite
surface antigens, and leads to activation of monocytes
with subsequent release of pro-inflammatory cytokinesthat could further enhance parasite clearance in vivo.
We show for the first time that opsonic phagocytosis
of merozoites by mononuclear cells was strongly corre-
lated with disease outcomes in longitudinal studies of
children in Africa and was associated with a broad
repertoire of antibodies to merozoite surface antigens.
Antibodies promoting phagocytosis were acquired with
increasing exposure to malaria and age, and were
boosted or induced following recent or current episodes
of P. falciparum infection, consistent with the acquisi-
tion of immunity. We demonstrate for the first time that
antibodies against MSP2 and MSP3 that were strongly
associated with protection in our study population, me-
diate opsonic phagocytosis of merozoites, providing an
important functional link between antigen-specific re-
sponses and immunity that has been lacking in the
field. The illustration of a temporal relationship between
functional immune responses and protective immunity,
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Figure 5 The relative phagocytosis index (RPI) is correlated with malaria exposure and boosted by infection. (A) The prevalence of
antibodies promoting phagocytosis in children with and without concurrent asymptomatic parasitemia. Samples were considered positive for
phagocytosis if the RPI exceeded the mean plus three standard deviations of a panel of 10 non-malaria exposed sera from Melbourne blood donors.
(B) The RPI increased significantly with age in the Ngerenya cohort, Cuzick non-parametric test for trend across ordered groups, z = 7.86, P <0.001.
(C) The RPI increased modestly with age among parasite positive children in the Chonyi cohort, Cuzick test for trend across ordered groups, z = 1.24,
P = 0.214. The levels of antibodies promoting phagocytosis were higher (D) in children with asymptomatic parasitemia (parasite positive) than in
those without (parasite negative), and (E) in children with exposure to parasites in the preceding six months (recent infection) than in those without
(no recent infection). White boxes, parasite negative; grey boxes, parasite positive. (F) The RPI was higher in age-matched parasite positive children
from the high transmission cohort (Chonyi, grey boxes), compared to the low transmission cohort (Ngerenya, white boxes). Ngerenya cohort, n = 287;
Chonyi cohort, n = 109.
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that these responses contribute to malaria immunity.
Our results support merozoite OPA as a valuable
biomarker for human immunity that could be extended
to the evaluation of blood-stage vaccines in preclinical
studies and clinical trials. We confirmed that our assays
distinguished internalized and phagocytosed merozoites
from those merely attached to the surface of monocytes
using the pH sensitive dye pHrodo™. Imaging by scan-
ning electron microscopy provided further evidence of
phagocytosis of monocytes and the first high-resolution
images of this process. We further confirmed that
phagocytosis of merozoites using THP-1 cells mirrors
that obtained using freshly-isolated human monocytes.
We tested this in four different donors, and although
the level of phagocytosis varied among them, it was
consistently higher when tested with malaria-immune,
compared to non-malaria exposed, sera. Using the THP-1
cell line enables greater standardization and reproducibil-
ity of assays, reduces issues of assay variation encounteredusing monocytes from different donors [50-52], and
allowed sufficient quantities of monocytic cells to be
obtained conveniently from culture, as others have reported
recently [53]. In addition, we used recently-developed
methods for the purification of intact viable merozoites
in high numbers [34,35] to facilitate more precise as-
says. The biggest challenges we faced in performing
the OPA were the maintenance of a healthy parasite
culture and the optimization of methods to purify whole
merozoites. Once these procedures were optimized, two
people working together were able to test two 96-well
plates in a single run, with each sample assayed in dupli-
cate. Thus, the assay could potentially be efficiently per-
formed for large field trials.
Using a prospective longitudinal study design in a popu-
lation with medium-to-high malaria transmission levels, we
found that children with high levels of opsonic phagocytosis
antibodies had a greatly reduced risk of malaria compared
to those with low levels. Furthermore, opsonic phagocytosis
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Figure 6 Antibodies promoting phagocytosis are associated with a reduced risk of malaria in the Chonyi cohort. Children were
categorized into tertiles according to their (A) relative phagocytosis index, (B) ELISA IgG1 optical density (OD) levels against whole merozoites
and (C) ELISA IgG3 OD levels against whole merozoites. Top tertile (red line), middle tertile (green line) and bottom tertile (yellow line) levels.
Phagocytosis of merozoites was significantly associated with a reduced risk of malaria (log rank test P = 0.007), while IgG subclass antibodies
against whole merozoites were not (log rank test P = 0.914 and P = 0.396, for IgG1 and IgG3, respectively). (D) The phagocytosis index, (E) whole
merozoite IgG1 and (F) whole merozoite IgG3 antibodies were significantly associated with the sum of IgG responses against any one of MSP2,
MSP3, MSP119, AMA1, EBA175 and MSP1 block 2 [6] in the Chonyi cohort. Cuzick test for trend across ordered groups, z = 2.98, P = 0.004;
z = 5.56, P <0.001 and z = 6.36, P <0.001, for the RPI, IgG1 and IgG3 against merozoites respectively. AMA1, apical membrane antigen 1; EBA,
erythrocyte binding antigen; MSP, merozoite surface protein; OD, optical density.
Table 1 Strength of association between measures of
immunity and the risk of clinical episodes of malaria in
the Chonyi cohort
Antigen Hazard ratio (95% CI) P value
RPI 0.25 (0.10 to 0.60) 0.002
Merozoite IgG1 1.09 (0.46 to 2.55) 0.834
Merozoite IgG3 0.53 (0.21 to 1.34) 0.185
MSP119 0.89 (0.43 to 1.87) 0.776
MSP2 0.15 (0.04 to 0.47) 0.001
MSP3 0.31 (0.11 to 0.86) 0.026
AMA1 0.25 (0.10 to 0.61) 0.002
EBA175 0.47 (0.19 to 1.14) 0.095
MSP1 block 2 0.46 (0.18 to 1.18) 0.109
Hazard ratios comparing the risk of a clinical episode of malaria between
children who had the top versus bottom tertile of antibody responses against
each antigen. ELISA antibody responses against parasite schizont extract were
highly correlated (Spearman’s rho = 0.764, P <0.001 and 0.730, P <0.001 for
IgG1 and IgG3, respectively) with those against whole merozoite IgG and are
not included in this table. AMA1, apical membrane antigen 1; CI, confidence
interval; EBA, erythrocyte binding antigen; MSP, merozoite surface protein; RPI,
relative phagocytosis index. Chonyi cohort, n = 109.
Table 2 Multivariate analysis including all antibody
measures of immunity in the Chonyi cohort
Antigen Hazard ratio (95% CI) P value
RPI 0.20 (0.07 to 0.59) 0.003
Merozoite IgG1 2.16 (0.25 to 18.6) 0.482
Merozoite IgG3 0.79 (0.07 to 8.11) 0.844
MSP119 1.66 (0.42 to 6.53) 0.464
MSP2 0.15 (0.03 to 0.69) 0.015
MSP3 0.98 (0.30 to 3.14) 0.981
AMA1 0.62 (0.12 to 3.21) 0.578
EBA175 0.72 (0.15 to 3.51) 0.694
MSP1 block 2 0.55 (0.15 to 1.90) 0.345
Hazard ratios comparing the risk of a clinical episode of malaria between
children who had the top versus bottom tertile of antibody responses against
each antigen. Chonyi cohort, n = 109. A similar analysis but including only
variables that were significant in the univariate analysis (Table 1) did not alter
these results and is presented in Additional file 1: Table S1. AMA1, apical
membrane antigen 1; CI, confidence interval; EBA, erythrocyte binding antigen;
MSP, merozoite surface protein; RPI, relative phagocytosis index.
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Table 3 Phagocytosis of merozoites is associated with a lower risk of multiple episodes of malaria in the low malaria
transmission cohort
Ngerenya children First episode Multiple episodes
IRR (95% CI) P IRR (95% CI) P
Merozoite Phagocytosis
Whole cohort (n = 287) 1.25(0.89 to 1.77) 0.186 1.17(0.61 to 2.24) 0.618
Recent exposurea (n = 81) 0.95(0.52 to 1.73) 0.888 0.34(0.13 to 0.85) 0.022
Recent exposureb (n = 40) 0.44(0.19 to 1.01) 0.055 0.13(0.03 to 0.46) 0.001
Merozoite ELISA
Whole cohort (n = 287) 1.12(0.73 to 1.72) 0.582 1.18(0.58 to 2.40) 0.641
Recent exposurea (n = 81) 0.77(0.27 to 2.14) 0.618 0.54(0.09 to 3.12) 0.493
Antibodies promoting phagocytosis of merozoites were fitted to age-adjusted multivariate regression models. Results are shown as incidence rate ratios (IRR), 95% confidence
intervals (CIs) and P values. a,bChildren with documented exposure to malaria parasites in the preceding six and three months, respectively. Nearly all children
with recent exposure (38/40) in the preceding three months were positive for anti-merozoite IgG by ELISA. Significant results at P < 0.05 are indicated in bold.
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ous findings that the breadth and magnitude of the anti-
merozoite antibody response is important in immunity
[6]. In contrast, total IgG or IgG-subclass reactivity to the
surface of whole merozoites was not significantly associated
with protection. This emphasizes the importance of
measuring antibody function in evaluating immunity.
The finding that antibodies to some, but not all, mero-
zoite antigens were associated with protection from
malaria supports the argument that only a subset of
antigens may be key targets for protective immunity.
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Figure 7 Merozoite surface antigens are targets of opsonic
phagocytosis antibodies. Affinity purified human antibodies
against MSP2 and MSP3 strongly promote opsonic phagocytosis in a
concentration dependent fashion. Antibodies purified from pooled
sera from Kenyan adults from Ngerenya village, n = 20. MSP,
merozoite surface protein.protective and non-protective responses, which may
explain why it was not strongly predictive of immunity.
A further strength and novel aspect of our study was
the inclusion of a second cohort study in a lower trans-
mission setting that enabled additional assessments of
the acquisition and boosting of responses and their rela-
tionship to protective immunity. Opsonic phagocytosis
here was lower than in the medium-to-high transmission
cohort, and is highly relevant to understanding how
changes in malaria transmission impact on functional
immunity, a priority issue given global changes in mal-
aria transmission. Children who generated higher levels
of opsonic phagocytosis in response to infection had a
reduced risk of multiple episodes of malaria. This pro-
vides the first evidence that recent infections boost or
induce opsonic phagocytosis to protective levels in chil-
dren as they acquire immunity, supporting the notion that
repeated exposure is a prerequisite for the development of
highly effective immunity.
Opsonic phagocytosis may contribute to immunity by
direct clearance of merozoites, thereby reducing parasit-
emia, as well as broader immunologic effects. We dem-
onstrated that opsonic phagocytosis of merozoites leads
to monocyte activation and production of the pro-
inflammatory cytokine TNF-α, a phenotype characteristic
of classically-activated (M1) monocytes/macrophages that
mediate defense against a range of infectious pathogens
[54]. TNF-α is known to upregulate inducible nitric oxide
synthase expression and nitric oxide production to enhance
parasite killing, and studies in animal models point to an
important role for TNF-α in parasite clearance [55].
A lack of functional assays to evaluate antibodies to
merozoite antigens has been a barrier to understanding
malaria immunity and vaccine development. Field
studies and vaccine trials have relied on GIAs to evalu-
ate functional activity of antibodies to merozoite anti-
gens, but these do not reliably correlate with protective
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In contrast, opsonic phagocytosis closely matched the
features of acquired human immunity and was strongly
associated with protective immunity as highlighted by
multivariate analysis including all antibody parameters,
suggesting that it is a better functional biomarker of
immunity in humans. The antibody-dependent cellular
inhibition (ADCI) assay, another potential functional
correlate of immunity, measures the overall effect of
antibodies and monocytes on in vitro growth of parasites
[18] and may include responses to merozoites and soluble
antigens and complexes, but its importance has not yet
been evaluated in prospective longitudinal cohort studies.
The ADRB assay, in which neutrophils are the antibody-
dependent effector cells, was recently shown to correlate
with protection from clinical episodes of malaria in two
cohorts experiencing differing levels of malaria transmis-
sion intensity [14]. Release of reactive oxygen species
measured in this assay is thought to reflect neutrophil
phagocytosis of opsonized merozoites, but the quanti-
tative relationship between the two processes has not
been clearly established [14]. Unlike our study, ADRB
activity was higher in parasite negative compared to
parasite positive children, a somewhat unusual finding
given that ADRB activity was dependent on antibodies
and parasite positive children have been consistently
shown to have higher antibody levels than their parasite
negative counterparts in many studies. Furthermore, al-
though ADRB was positively correlated with anti-merozoite
antibodies, the correlation coefficients were considerably
lower than those we observed for the OPA. Lastly, it was
unclear whether or not ADRB activity was correlated with
age, as might be expected from observed epidemiological
patterns of immunity. The technical challenges of
obtaining adequate amounts of fresh neutrophils, and
using them within a few hours of collection for high
throughput assays, make the ADRB assay technically
challenging in its current format.
Conclusions
In conclusion, this study provides several important new
lines of evidence that the ability of antibodies to opsonize
merozoites for phagocytosis by monocytes, by targeting
major merozoite antigens, is an important mechanism
contributing to the control of P. falciparum parasitemia
in vivo and protection from malaria. This study provides
major new advances in our understanding of mecha-
nisms underlying acquired immunity and establishes the
OPA as an important biomarker of blood-stage immunity
for accelerating the development and evaluation of mal-
aria vaccines. Using vaccine approaches and targets that
can induce strong opsonic phagocytosis activity may be
an important strategy in the development of highly ef-
ficacious malaria vaccines.Additional file
Additional file 1: Supplementary information. Additional analyses
fitting only responses identified as significant to a single multivariate
model. Figures showing a time-course phagocytosis experiment and
reproducibility of the opsonophagocytosis assay.
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